Xenon Pharmaceuticals (XENE) Equity Average (2014 - 2026)

Xenon Pharmaceuticals (XENE) has 13 years of Equity Average data on file, last reported at $959.8 million in Q1 2026.

• Equity Average for Q1 2026 came in at $959.8 million, up 31.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $959.8 million (up 31.58% YoY), and the FY2025 annual result was $668.3 million, down 20.57% from the prior year.
• Equity Average rose to $959.8 million in Q1 2026 per XENE's latest filing, from $570.6 million in the prior quarter.
• Over five years, Equity Average peaked at $959.8 million in Q1 2026 and troughed at $545.9 million in Q1 2022.
• A 5-year average of $729.9 million and a median of $729.4 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average jumped 204.18% in 2022, then declined 27.31% in 2025.
• A 5-year view of Equity Average shows it stood at $737.3 million in 2022, then grew by 6.1% to $782.3 million in 2023, then fell by 0.75% to $776.4 million in 2024, then slipped by 26.5% to $570.6 million in 2025, then soared by 68.2% to $959.8 million in 2026.
• Business Quant data shows XENE's Equity Average at $959.8 million in Q1 2026, $570.6 million in Q4 2025, and $596.7 million in Q3 2025.